A system for preventing and controlling diabetic nephropathy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This project focuses on diabetic nephropathy, a severe complication of diabetes that leads to significant health issues and resource consumption. It aims to establish a comprehensive regulatory system that covers the entire disease cycle of diabetic nephropathy by integrating large-sample natural population cohorts and prospective follow-up cohorts. The goal is to create a panoramic life database to identify risk factors, clinical phenotypes, and multimodal biomarkers associated with the disease. This approach addresses the current lack of representative cohorts and aims to improve understanding and management of diabetic nephropathy.

Why it matters

Who can join: the full rules

T2DM

Inclusion Criteria:

* Age ≥18 years old, gender is not limited
* Diagnosed with type 2 diabetes
* A history of type 2 diabetes for more than 5 years
* Negative proteinuria
* Creatinine is normal
* Good compliance, voluntarily sign informed consent

Exclusion Criteria:

* Incomplete medical records
* Lack of fundus microvascular examination or new imaging technology examination results data
* Combined with autoimmune diseases and tumors

Type 2 diabetes patients undergoing renal biopsy

Inclusion Criteria:

* Age ≥18 years old, gender is not limited
* Diagnosed with type 2 diabetes
* Kidney damage (microalbuminuria or dominant albuminuria or renal insufficiency)
* Have undergone renal puncture biopsy and have complete renal pathological diagnosis data
* Sign informed consent voluntarily

Exclusion Criteria:

* Gestational diabetes mellitus, special type diabetes mellitus
* Patients with hereditary kidney disease
* Combined with autoimmune diseases
* Diabetic nephropathy The indicators in the comprehensive assessment model of the risk of renal progression could not be obtained
* There were pregnancy plans in the study period

Where it's running

• Chinese PLA General Hospital
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Study coordinator: Zheyi Dong, MD
• Email: shengdai26@163.com
• Phone: +86 13810261592

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Umbilical Cord Mesenchymal Stem Cells for Diabetic Kidney Disease

  This study tests whether injecting human umbilical cord mesenchymal stem cells can help people with diabetic nephropathy by reducing kidney inflammation and damage.

  Recruiting Phase 1 Tongji Hospital · Wuhan · NCT07822152

• Lactoferrin Supplement in Diabetic Kidney Disease

  Scientists test whether adding lactoferrin helps people with diabetic nephropathy who also have moderately to severely increased urinary albumin.

  Recruiting Phase 2 Ain Shams University · Cairo · NCT07764991

• HRS9531 tablets for adults with type 2 diabetes not controlled by lifestyle or metformin

  This trial tests whether HRS9531 tablets help people with type 2 diabetes who have not reached their blood sugar goals on lifestyle changes or on metformin alone.

  Recruiting at 2 sites Phase 2 Fujian Shengdi Pharmaceutical Co., Ltd. · Beijing, Beijing Municipality and 1 other locations · NCT07599410

• HM15275 in adults with type 2 diabetes who have not yet reached goal

  This phase 2 trial tests HM15275 or a placebo to see if it helps adults with type 2 diabetes improve blood sugar over 36 weeks.

  Recruiting at 20 sites Phase 2 Hanmi Pharmaceutical Company Limited · Mesa, Arizona and 19 other locations · NCT07527650

• HTD1801 vs placebo for kidney protection in type 2 diabetes and CKD

  This trial tests whether HTD1801 can slow kidney decline in adults with type 2 diabetes and chronic kidney disease.

  Recruiting Phase 2 Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences · Weifang, Shandong · NCT07496177

• Single-dose exenatide circular RNA in lipid nanoparticles for Chinese adults with type 2 diabetes

  This test gives a single injection of CR059 (exenatide circular RNA in a lipid nanoparticle) to see if it is safe and how it behaves in Chinese adults with type 2 diabetes.

  Recruiting Early Phase 1 The First Affiliated Hospital of Henan University of Science and Technology · Luoyang, Henan · NCT07347080

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.